| 摘要 |
The invention provides alpha-mimetic structure of formula (I), wherein A is -(C-O)-(CHR3)- or -(C-O)-; B is -(NR5)- or -(CHR6)-; D is -(C-O)-(CHR7)- or -(C-O)-; E is -(ZR8)- or -(C-O)-, where Z is nitrogen or CH; -(XR9)n-, -(CHR10)-(NR6)-, -(C-O)-(XR12)-, -(C-N-W-R1)-, -(C-O)-, -(X-(C-O)-R13)-, -(X-(C-O)-NR13R14)-, -(X-(SO2)-R13)-, or -(X-(C-O)-OR13)-, where X is nitrogen or CH, and n=0 or 1; W is -Y(C-O)-, -(C-O)-(NH)-, -(SO2)-, -(CHR14)-, -(C-O)-(NR15)-, substituted or unsubstituted oxadiazole, substituted or unsubstituted triazole, substituted or unsubstituted thiadiazole, substituted or unsubstituted 4,5-dihydrooxazole, substituted or unsubstituted 4,5-dihydrothiazole, substituted or unsubstituted 4,5-dihydroimidizole, or nothing, where Y is oxygen or sulfur; and R1, R2, R3, R4, R5, R6, R7, R8, R9 R10, R11, R12, R13, R14, and R15 are the same or different and independently selected from an amino acid side chain moiety or derivative thereof, the remainder of the molecule, a linker and a solid support, and stereoisomers, salts, and prodrugs thereof, provided that where B is -(CHR6) and W is -Y(C-O)-, -(C-O)-(NH)-, -(SO2)-, -(CHR14)-, or -(C-O)-(N15)-, G cannot be -(CHR9)-, -(NR9)-, -(C-O)-(CHR12)-, -(C-O)-(NR12)-, or no atom at all. Additionally, the invention provides methods wherein alpha-mimetic compounds are used to treat a disease or pathological condition.
|
